Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bronchodilator selection in newly diagnosed moderate-to-severe COPD after short-acting beta-agonist reversibility testing
ChiCTR-IPR-15006011Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tiotropium, formoterol, budesonide and salbutamol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Absolute increase in FEV1. Planned start Jan 2015; status: not yet recruiting.
02
Drugs
tiotropiumformoterolbudesonidesalbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR-IPR-15006011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006011.